Breast cancer (Bc) is the leading cause of cancer-related death among women and the most commonly diagnosed cancer worldwide. Although in recent years large-scale efforts have focused on identifying new therapeutic targets, a better understanding of BC molecular processes is required. Here we focused on elucidating the molecular hallmarks of BC heterogeneity and the oncogenic mutations involved in precision medicine that remains poorly defined. To fill this gap, we established an OncoOmics strategy that consists of analyzing genomic alterations, signaling pathways, protein-protein interactome network, protein expression, dependency maps in cell lines and patient-derived xenografts in 230 previously prioritized genes to reveal essential genes in breast cancer. As results, the OncoOmics BC essential genes were rationally filtered to 140. mRNA up-regulation was the most prevalent genomic alteration. The most altered signaling pathways were associated with basal-like and Her2-enriched molecular subtypes . RAC1, AKT1, CCND1, PIK3CA, ERBB2, CDH1, MAPK14, TP53, MAPK1, SRC, RAC3,  BCL2, CTNNB1, EGFR, CDK2, GRB2, MED1 and GATA3 were essential genes in at least three oncoomics approaches. Drugs with the highest amount of clinical trials in phases 3 and 4 were paclitaxel, docetaxel, trastuzumab, tamoxifen and doxorubicin. Lastly, we collected ~3,500 somatic and germline oncogenic variants associated with 50 essential genes, which in turn had therapeutic connectivity with 73 drugs. In conclusion, the OncoOmics strategy reveals essential genes capable of accelerating the development of targeted therapies for precision oncology.
Results
OncoPrint of genomic alterations according to the Pan-Cancer Atlas. PCA has reported the clinical data of 1084 individuals with BC and it can be visualized in the Genomic Data Commons of the National Cancer Institute and in the cBioPortal 47, 48 . In regard to molecular subtypes and tumor stages, 46% were lumina A, 18% luminal B, 7% Her2-enriched, 16% basal-like and 3% normal-like, whereas 17% were tumor stage 1 (T1), 58% T2 stage, 23% T3 stage and 2% T4 stage ( Supplementary Table S1 ). Figure 1a shows the frequency mean of genomic alterations per gene set. The frequency mean of the PCA gene set was 1.3, followed by the CS gene set (1.2), the PharmGKB/CGI gene set (1.0), BC driver genes (0.8), and non-cancer genes (0.4) ( Supplementary Table S2 ). Consequently, we performed a multiple comparison of the genomic alteration frequencies using the Bonferroni correction in order to determine statistical significance among gene sets. There were significant differences between BC driver genes and non-cancer genes (P < 0.001), the PCA gene set and BC driver genes (P < 0.001), and the CS gene set and BC driver genes (P < 0.001). Hence, the fact that gene sets of interest (CS and PCA) presented significant differences in the amount of genomic alterations versus BC driver genes could indicate that we are analyzing potentially essential genes in BC. Figure 1b shows the percentage of genomic alterations per type. The most common genomic alterations were mRNA up-regulation (55.8%), CNV amplification (17.1%), and missense mutations (8.4%). Figure 1c shows the ratio of genomic alterations in the 230 genes per sample and molecular subtype. Basal-like had the highest ratio (n = 33), followed by Her2-enriched (29) , luminal B (24) , normal-like (17) , and luminal A (15) . The ratio of all BC samples was 19.6. Figure 1d shows the ratio of genomic alterations in the 230 genes per sample and tumor stage. T2 stage had the highest ratio (23), followed by T3 (22) , T1 (17) and T4 (8) . Figure 1e ,f show the percentage of genomic alterations per subtype and tumor stage, respectively. mRNA up-regulation and CNV amplification were the most common alterations in all molecular subtypes and tumor stages. Figure 2 shows the ranking of genes with the highest amount of genomic alterations per molecular subtype and tumor stage. Regarding molecular subtypes, PIK3CA was the most altered gene in luminal A, CCND1 in luminal B, TP53 in basal-like and normal-like, and ERBB2 in Her2-enriched ( Fig. 2a) . Figure 2b-f show genes with the highest ratio of mutations, CNV amplifications, CNV deep deletions, mRNA up-regula tions, and mRNA down-regulations per molecular subtype (Tables S3-S7 ). After Bonferroni correction, we obtained statistically significant differences (P < 0.05) regarding CNV amplifications, CNV deep deletions, mRNA up-regulations, and mRNA down-regulations among molecular subtypes. On the other hand, the most altered genes per tumor stage were PIK3CA in T1 stage, TP53 in T2 and T3, and ERBB2 in T4 (Fig. 2g ). Figure 2h -l show genes with the highest percentage of mutations, CNV amplifications, CNV deep deletions, mRNA up-regulations, and mRNA down-regulations per tumor stage (Tables S8-S12). We found statistically significant differences (P < 0.05) regarding all genomic alterations among tumor stages using the Bonferroni correction test.
The first OncoOmics approach was focused on genes with the highest amount of genomic alterations (more than the average). The panoramic landscape of genomic alterations was termed OncoPrint and is shown in Fig. 3a .
Putative driver mutations were taken into account for this analysis, discarding passenger mutations ( Figure S1 and Supplementary Table S13 ). Figure 3b ,c show circos plots of interactions among molecular subtypes, tumor stages, and genomic alterations of the most altered genes ( Supplementary Table S14 ). Highest amount of fusion genes were in Her2-enriched subtype and T4 stage, highest amount of mRNA down-regulation + CNV deep deletion were in basal-like subtype and T4 stage, highest amount of mRNA up-regulation + CNV amplification were in basal-like subtype and T4 stage, lastly, highest amount of putative driver mutations were in Her2-enriched subtype and T3 stage. As result, the first OncoOmics approach reveled 73 essential genes with highest frequencies of genomic alterations. T1  T2  T3  T4   0   10   20   30   40   T1  T2  T3  T4   0   5   10   15   T1  T2  T3  T4   0   2   4   6   8   T1  T2  T3  T4   0   5   10   15   20   T1  T2  T3  T4   2   4   6   8   10   T1  T2  T3  T4 PIK3CA 
Pathway enrichment analysis. This enrichment analysis was performed using David Bioinformatics
Resource to obtain integrated information from the Kyoto Encyclopedia of Genes and Genomes (KEGG) [49] [50] [51] [52] . The enrichment analysis of signaling pathways was carried on in the 230 genes, obtaining more than 50 terms with a Benjamini-Hochberg -false discovery rate (FDR) <0.01 ( Supplementary Table S15 ). Subsequently, genomic alterations of genes that make up each signaling pathway were analyzed according to the molecular subtype and tumor stage. Figure 4a shows a circos plot correlating molecular subtypes with signaling pathways ARID1A  ATR  BLM  BRCA1  BRCA2  BRIP1  CDH1  CDKN2A  EP300  NF1  NF2  PMS2  RB1  RNF43  SPOP  CREBBP  NOTCH2  PTEN  TP53  ABL1  AKT1  CCND1  ERBB2  FGFR1  KRAS  MAPK1  PIK3CA  RAC1  GATA3  KMT2C  MDM4  MLH1  NBN  NCOA2  PALB2  PLCG1  SF3B1  SMARCE1  SRC  WWTR1  AKT3  AP1S1  CARM1  EPCAM  FCGR2A  FCGR3A  FGF3  FGF4  GRB2  GSTP1  HMGB1  LARP7  MAP3K1  MAPK14  MED1  MRE11  NCOA6  NIPBL  PDPK1  PIGB  PPP2R5D  RAC3  RAD51C  RECQL  RELA  RNF8  RPA1  TNFRSF11B  TOP2A  TOP3A  TUBB1  ZC3H13 ( Supplementary Table S16 ). NF-kappa ß, NOD-like receptor, adipocytokine, GnRH, RIG-like receptor, TNF, TGFß, FOXO, glucagon, MAPK, prolactin, cAMP, PI3K-AKT, neurotrophin, VEGF, notch, p53, sphingolipid and Wnt signaling pathways were more altered in basal-like; estrogen, HIF1, toll-like receptor, ras, insulin, T-cell receptor, rap1, ERBB, AMPK, chemokine, B-cell receptor, mTOR, Fc-epsilon RI, Jak-STAT, phosphatidylinositol and thyroid hormone pathways were more altered in Her2-enriched; and Hippo pathway in normal-like. On the other hand, Fig. 4b shows the ranking of the most altered signaling pathways per molecular subtype. Jak-STAT pathway was more altered in luminal A; Wnt pathway in luminal B; p53 pathway in basal-like; ERBB pathway in Her2-enriched; and Hippo pathway in normal-like ( Supplementary Table S17 ). After Bonferroni correction, we observed statistically significant differences (P < 0.001) regarding the amount of genomic alterations in signaling pathways among molecular subtypes. Figure 4c shows a circos plot correlating tumor stages with signaling pathways according to the frequency of genomic alterations ( Supplementary Table S16 ). NOD-like receptor, adipocytokine, GnRH, TNF, estrogen, prolactin, FOXO, glucagon, ras, MAPK, T-cell receptor, cAMP, rap1, PI3K-AKT, B-cell receptor, VEGF, mTOR, Fc epsilon RI, NOTCH, p53, sphingolipid and Wnt pathways were more altered in stage T2; NF-kappa ß, Hippo and phosphatidylinositol pathways were more altered in T3 stage; and RIG-like receptor, HIF1, TGFß, toll-like receptor, insulin, AMPK, ERBB, chemokine, neurotrophin, mTOR, jak-STAT and thyroid hormone pathways were more altered in T4 stage. On the other hand, Fig. 4d shows the ranking of the most altered signaling pathways per tumor stage. Wnt pathway was more altered in T1, T2 and T3 stages; and thyroid hormone pathway was more altered in T4 stage ( Supplementary Table S18 ). We found statistically significant differences (P < 0.001) regarding the amount of genomic alterations in signaling pathways among different tumor stages using the Bonferroni correction test.
Protein-protein interactome network. The second OncoOmics approach was focused on proteins with the highest degree centrality and consensus score in the String PPi network. The PPi network was performed to better understand BC behavior using the String Database and Cytoscape 53, 54 . With the indicated cutoff of 0.9, the final interactome network had 258 nodes conformed by 198 (86%) proteins from the CS, PCA and PharmGKB/ CGI sets. Regarding nodes with the highest amount of genomic alterations showed previously in the OncoPrint, 65 (89%) of them integrated this network ( Fig. 5a ). On the other hand, out of the 258 proteins that make up our String PPi network, 16 (6%) proteins and 18 edges were part of the OncoPPi BC network 55, 56 . The degree centrality made it possible to establish a significant correlation (Spearman test, P < 0.05) between our String PPi network and the OncoPPi BC network ( Fig. 5b ).
Considering degree centrality and consensus scores from our previous study 29 , there was enrichment among sub-networks ( Fig. 5a,b ). The degree centrality average in the whole network was 48.8, and out of the OncoPPi BC network was 124.4. Meanwhile, the average of consensus score of the whole network was 0.803, and out of the OncoPPi BC network was 0.885. As result, the second OncoOmics approach reveled 40 proteins with both the highest degree centrality and consensus score, as shown in Supplementary Table S19 .
Protein expression analysis. The third OncoOmics approach was focused on proteins with considerable high and low expressions in BC. Figure 6a shows 43 proteins with significant high expression (Z-scores ≥ 2) and low expression (Z-scores ≤ −2) analyzed with the reverse-phase protein array (RPPA) and mass spectrometry, in a cohort of 994 individuals according to TCGA ( Supplementary Table S20 ). On the other hand, the Human Protein Atlas (HPA) presented a map of the human tissue proteome based on tissue microarray-based immunohistochemistry. HPA has analyzed 202 (88%) of the 230 proteins of our study, classifying the protein expression in high, medium, low and non-detected. As results, RAC1, GJB2, MED1, PIK3CA, PIK3R3, FGFR2, HCFC2, MAP2K4, NQO2 and RAC3 were proteins with high/medium expression in normal tissue, and low/ non-detected expression in BC tissue. Meanwhile, CDK2, CYP2D6, NCOR1, RRM1, FOXA1 and TOP2A were proteins with hi gh/medium expression in BC tissue, and low/non-detected expression in normal tissue (F ig. 6b and Supplementary Table S21 ) 57, 58 . As result, the third OncoOmics approach revealed 60 proteins with significant altered expression levels as shown in Tables S20 and S21.
Breast cancer dependency map. The first analysis of the fourth OncoOmics approach consisted in identifying genes that are essential for breast cancer cell proliferation and survival performing systematic loss-of-function screens in a large number of well-annotated cell lines representing the tumor heterogeneity [19] [20] [21] [22] . Figure 7a shows the distribution of dependency scores of 227 genes through DEMETER2, an analytical framework for analyzing genome-scale RNAi loss-of-function screens in 73 BC cell lines ( Supplementary Table S22 ). Our results showed 563 dependencies with at least one score ≤ −1 in 57 (25%) essential genes. At the same time, Fig. 7a shows the distribution of dependency scores of 217 genes through CERES, an analytical framework for analyzing genome-scale CRISPR-Cas9 loss-of-function screens in 28 BC cell lines ( Supplementary Table S23 ). Our results showed 310 dependencies with at least one score ≤ −1 in 34 (16%) essential genes. Figure Figure 7c shows violin plots of dependencies per molecular subtype. DEMETER2 has detected a greatest number of substantial dependencies in basal-like, followed by Her2-enriched, luminal A and luminal B, whereas CERES has detected a greatest number of substantial dependencies in basal-like, followed by luminal A and Her2-enriched. Figure 7d shows a Venn diagram of 22 strongly selective genes, 26 common essential genes, and 5 strongly selective and common essential genes in breast and other cancer cell lines.
Patient-derived xenografts. The second analysis of the fourth OncoOmics approach consisted in identifying proteins with significant expression in PDXs. According to Woo et al., PDXs are in vivo models of human cancer that are useful for translational cancer research and therapy selection for individual patient. We analyzed the 66 strongly selective and common essential genes of BC cell lines using the Jackson Laboratory PDX resource 59 . Figure 7e shows 7 proteins with significant high expression (Z-score ≥ 2) and 33 proteins with significant low expression (Z-scores ≤ −2) with its respective mice model ID. As result, the fourth OncoOmics approach revealed 38 proteins with significant expression in both BC cell lines and patient-derived xenografts ( Supplementary Tables S22 and S23 ).
OncoOmics approaches to reveal essential genes in BC.
After analyses of the four OncoOmics approaches (genomic alterations, String PPi network, protein expression and BC dependencies/patient-derived xenografts), we used a Venn diagram to integrate essential genes, termed OncoOmics BC essential genes. Consequently, we could observe 140 essential genes in at least one OncoOmics approach; of them, 92 were essential in one OncoOmics approach, 30 were essential in two OncoOmics approaches, 13 were essential in three OncoOmics approaches, and 5 were essential in all OncoOmics approaches as shown in Fig. 8a and Supplementary Table S24 .
The 140 OncoOmics BC essential genes were conformed by oncogenes (21%), tumor suppressor genes (24%) and driver genes in other cancer types (59%) 60 (Fig. 8b) . Additionally, some of these OncoOmics BC essential genes were involved in cancer immunotherapy 61 , kinome signaling 62 , cell cycle 63 , DNA repair 64 and RNA-binding as shown in Fig. 8c and Supplementary Table S25 65 . Figure 8d shows a circos plot detailing the correlation between 48 (34%) OncoOmics BC essential genes and hallmarks of cancer. Suppression of growth was promoted by AKT1, CTNNB1, PTEN, RB1 and TP53; escaping
Nodes with the highest degree of centrality (> 52.7)
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Nodes with the highest consensus scores and degree of centrality www.nature.com/scientificreports www.nature.com/scientificreports/ immune response to cancer was promoted by CTNNB1, EGFR and RAC1; cell replicative immortality was promoted by CTNNB1, KRAS and NOTCH1; tumor promoting inflammation was promoted by KRAS; metastasis was promoted by ABL1, CTNNB1, EGFR, KRAS, RAC1 and RB1; angiogenesis was promoted by ABL1, CTNNB1, EGFR, KRAS, NOTCH1 and RAC1; genome instability was promoted by ABL1 and RB1; escaping programmed cell death was promoted by AKT1, CTNNB1, EGFR, NOTCH1; change of cellular energetics was promoted by ABL1, AKT1, CTNNB1, EGFR, KRAS, NOTCH1, PTEN, RB1 and TP53; finally, proliferative signaling was promoted by ABL1, AKT1, CTNNB1, EGFR, KRAS, NOTCH and RAC1 ( Supplementary Table S26 ).
Enrichment map of the OncoOmics BC essential genes. Figure 8e shows the enrichment map of the 140 OncoOmics BC essential genes. g:Profiler searches for a collection of genes representing GO terms, pathways and disease phenotypes 66 . The most significant GO: biological processes with a FDR < 0.001 was positive www.nature.com/scientificreports www.nature.com/scientificreports/ regulation of macromolecule metabolic process ( Supplementary Table S27 ); the most significant GO: molecular function was phosphatidylinositol 3-kinase activity ( Supplementary Table S28 ); the most significant Reactome pathway was generic transcriptor pathway ( Supplementary Table S29) 67 ; additionally, the most relevant disease, according the Human Phenotype Ontology, was breast carcinoma ( Supplementary Table S30 ) 68 . Subsequently, g:Profiler annotations were analyzed with the EnrichmentMap software and visualized using Cytoscape, in order to generate network interactions of the most relevant GO: biological processes ( Supplementary Fig. S2 ) and Reactome pathways ( Fig. 9 ) related to immune system, tyrosine kinase, cell cycle and DNA repair pathways 54,66 . Clinical trials. Figure 10 and Supplementary Table S31 details the current status of clinical trials regarding OncoOmics BC essential proteins, according to the Open Targets Platform 69 . There are 98 drugs that are being analyzed in 2,904 clinical trials in 28 of 140 OncoOmics BC essential proteins (Fig. 10a ). The top 10 drugs with the highest number of clinical trials in process or completed were paclitaxel (370), trastuzumab (315), docetaxel 
Common essential CRISPR-Cas9 -CERES (262), doxorubicin (204), gemcitabine (196), lapatinib (152), tamoxifen (131), fulvestrant (129), bevacizumab (120) and neratinib (110) . Regarding drugs, 94% were antagonists, 79% were small molecules, and 35% were protein kinases as shown in Fig. 10b-d , respectively. Additionally, drugs with the highest number of clinical trials in phases 3 and 4 were paclitaxel (111), docetaxel (105), trastuzumab (80), tamoxifen (69) and doxorubicin (60) as shown in a Sankey plot detailed in Fig. 10e . www.nature.com/scientificreports www.nature.com/scientificreports/ Precision medicine. Precision oncology focuses on matching the most effective and safe treatment based on the 'omics' profile of each individual or population 70, 71 . However, the identification of driver mutational events remains the biggest challenge 72 . There are some consortiums and studies that have robustly identified variants associated with BC. Tamborero et al. detailed a compendium of 62 somatic and 398 germline validated oncogenic mutations in 14 OncoOmics BC essential genes ( Supplementary Table S32 ) 38 . Huang et al. identified 87 pathogenic germline variants in 22 OncoOmics BC essential genes 73 ( Supplementary Table S33 ). Long et al. 74, 75 , Cai et al. 76 , Michailidou et al. 77 , and the Breast Cancer Association Consortium performed genome-wide association www.nature.com/scientificreports www.nature.com/scientificreports/ studies identifying 172 germline variations related to BC development ( Supplementary Table S34 ). The Precision Medicine Knowledgebase (PreMedKB) detailed a compendium of 2791 germline variants in 7 OncoOmics BC essential genes ( Supplementary Table S35 ) 71 . PharmGKB enriched clinical guidelines with 59 well-known clinical annotations related to 29 OncoOmics BC essential genes ( Supplementary Table S36 ) 42, 78, 79 . Finally, the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium identified 19 non-coding somatic mutations and 17 coding somatic mutations in BC ( Supplementary Table S37 ) 6 .
Regarding the Ensembl Variant Effect Predictor 80 , 1,102 of 3,565 variants were processed, being 24% intron variants, 16% missense variants, 15% downstream gene variants, 10% stop gained, 7% upstream gene variants, 7% NMD transcript variants, 4% splice region variants, 4% 3′ untranstaled region variants, and 2% splice acceptor variants ( Supplementary Table S38 ).
Consequently, based on the aforementioned somatic and germline oncogenic variants, the Cancer Genome Interpreter and PreMedKB platforms provided a comprehensive in silico list of biological therapy drugs aimed to improve precision medicine in breast cancer (Fig. 11 , Tables S35 and S39 ). 
Discussion
In this study we reveal essential genes in breast cancer through an OncoOmics strategy that analyzes genomic alterations, PPi networking, protein expression, dependency maps and patient-derived xenografts in three gene sets. The first gene set was taken from our previous study where we developed a Consensus Strategy that was proved to be highly efficient in the recognition of BC pathogenic genes 29, 41 . The second gene set was taken from several studies of PCA, which provides a panoramic view of the oncogenic processes that contributes to BC pathogenesis 3, 13, [31] [32] [33] [34] [35] [36] [37] . The third gene set was taken from the CGI and PharmGKB. On the one hand, the CGI flags genomic biomarkers of drug response with different levels of clinical relevance 38 . On the other hand, PharmGKB collects clinical annotations applied in BC patients and taken from the NCCN, ESMO, CPNDS, DPWG and CPIC guidelines [43] [44] [45] [46] . Finally, the compendium of these 230 genes was analyzed through four different OncoOmics approaches. TOP2A   BRCA2  BRCA1  ESR1  ERBB1   INPP4B   NOTCH1   CDH1   PIK3R1   TNFRSF11B   IRS1   olaparib, veliparib,  cisplatin, Precision medicine Druggability of 50 OncoOmics BC essential proteins Figure 11 . Precision medicine. Interaction between drugs and 50 OncoOmics BC essential proteins.
The first OncoOmics approach consisted in the analysis of genomic alterations using the PCA data 47, 48 . The frequency mean of genomic alterations in the CS (1.2) and PCA (1.3) gene sets were significantly higher than both the non-cancer genes (0.4) and the well-known BC driver genes (0.8), with a significant Bonferroni correction of P < 0.001. This means that the analyzed set of genes might be strongly associated with BC (Fig. 1a) .
The most common genomic alterations in a cohort of 994 individuals were mRNA up-regulation, CNV amplification and missense mutations. Regarding molecular subtypes, basal-like showed the highest amount of genomic alterations. PIK3CA was the most altered gene in luminal A, CCND1 in luminal B, TP53 in basal-like and normal-like, and ERBB2 in Her2-enriched ( Fig. 2a) . A multiple comparison through Bonferroni correction found significant differences (P < 0.05) of CNV amplifications, CNV deep deletions, mRNA up-regulations, and mRNA down-regulations among molecular subtypes (Figs. 2c-f ). Regarding tumor stages, T2 showed the highest amount of genomic alterations. PIK3CA was the most altered gene in T1, TP53 in T2 and T3, and ERBB2 in T4 (Fig. 2g ). Bonferroni correction found significant differences (P < 0.05) in punctual mutations, CNV amplifications, CNV deep deletions, mRNA up-regulations, and mRNA down-regulations among tumor stages ( Fig. 2h-l) . Lastly, the first OncoOmics approach revealed that 73 essential genes presented frequencies of alteration higher than the average (Fig. 3a) 3, 13, [31] [32] [33] [34] [35] [36] [37] .
Subsequently, the enrichment analysis of signaling pathways was carried on taking into account all genomic alterations in the 230 genes using David Bioinformatics Resource and KEGG 49, 52 . Pathways with the highest amount of genomic alterations per molecular subtype were Jak-STAT in luminal A, Wnt in luminal B, p53 in basal-like, ERBB in Her2-enriched and Hippo in normal-like. Bonferroni correction showed significant differences (P < 0.05) among several subtypes as shown in Fig. 4b . On the other hand, pathways with the highest amount of genomic alterations per tumor stage were Wnt in T1, T2 and T3, and thyroid hormone in T4. Bonferroni correction showed significant differences (P < 0.05) comparing T1 with T2 and T4 as shown in Fig. 4d .
Regarding previously mentioned signaling pathways, Jak-STAT is involved in inflammatory response, stem cell maintenance, and hematopoiesis 81 . The Wnt signaling pathway actively functions in embryonic development and helps in homeostasis in mature tissues by regulating cell survival, migration, proliferation, and polarity 82 . The p53 signaling pathway plays an essential role into inhibition of growth, programmed cell death, cell migration and angiogenesis 83 . The ERBB pathway mediates signal transduction events that control cell survival, migration and proliferation in BC 84 . The Hippo pathway plays important roles in tumor suppression and immune response. However, alterations in this pathway are involved in the BC tumorigenesis and metastasis 85 . Lastly, the thyroid hormone pathway plays an important role as regulator of growth and metabolism. Nevertheless, dysfunction of the T3 hormone promotes cancer progression in mammary epithelial cells 86 .
The second OncoOmics approach was focused on proteins with the highest degree centrality and consensus score in the String PPi network. In accordance with Li et al. and Ivanov et al. 56, 87 , PPi with therapeutic significance can be revealed by the integration of cancer proteins into networks. PPi regulate essential oncogenic signals to cell proliferation and survival, and thus, represents potential targets for drug development and drug discovery. Regarding our networking analysis, the final interaction network consisted in 258 nodes with a degree centrality average of 48.8 and a consensus score average of 0.803 29 ; the sub-network integrated by 198 of 230 nodes had 52.7 of degree centrality and 0.812 of consensus scoring; finally, the sub-network integrated by 65 of 73 proteins with the highest amount of genomic alterations had 61.7 of degree centrality and 0.833 of consensus score. Hence, a sub-network of nodes with the highest amount of genomic alterations presented a highest degree centrality and consensus score, suggesting that there is strong correlation between these proteins and BC. Additionally, the oncogenomics validation showed a substantial correlation between our String PPi network ( Fig. 5a ) and the OncoPPi BC network (Fig. 5b) , identifying 16 nodes strongly associated with BC 29 . The second OncoOmics approach revealed 40 essential proteins with the highest degree centrality and consensus scoring.
The third OncoOmics approach was focused on proteins with significant high and low expression in BC proteome. More than 500 proteins have been identified as strongly involved in oncogenesis. Loss of expression, overexpression or expression of dysfunctional proteins contribute to uncontrolled tumor growth, causing chromosomal rearrangements, gene amplification and ungoverned methylation 88 . Regarding our 230 proteins, 43 showed significant high (Z-scores ≥ 2) and low (Z-scores ≤ −2) expression according to TCGA 89 (Fig. 6a) ; and 16 proteins showed opposite expression between healthy and affected tissues after microarray-based immunohistochemistry according to the Human Protein Altas (Fig. 6b) 57, 58 . The compendium of 60 proteins with significant high and low expressions made up the third OncoOmics approach.
The fourth OncoOmics approach was related to the BC dependency map in cell lines and patient-derived xenografts. According to Tsherniak et al., mutations that trigger the growth of cancer cells also confer specific vulnerabilities that normal cells lack, and these dependencies are compelling therapeutic targets 19 . The cancer dependency map identifies essential genes in proliferation and survival of well-annotated cell lines through systematic loss-of-function screens [19] [20] [21] [22] . On the one hand, DETEMER2 analyzed the genome-scale RNAi loss-of-function screens, and on the other hand, CERES analyzed the genome-scale CRISPR-Cas9 loss-of-function screens as shown in Fig. 7a . In addition to the loss-of-function screens in a large number of well-annotated BC cell lines, the patient-derived xenografts are in vivo models of human tumors engrafted in a mouse host and emerging as a powerful tool for understanding tumor hallmarks and predicting drug efficacy 90 . Consequently, we validated the genomic expression of the strongly selective and common essential genes (dependencies in BC cell lines) in breast tumors from PDXs provided by the Jackson Laboratory 59 . The fourth OncoOmics approach was made up of 38 essential proteins in BC (Fig. 7e) .
Subsequently, the compendium of essential genes per approach reveals the 140 OncoOmics BC essential genes (Fig. 8a) . RAC1, AKT1, CCND1, PIK3CA and ERBB2 were essential genes in all the OncoOmics approaches. CDH1, MAPK14, TP53, MAPK1, SRC and RAC3 showed genomic alterations, highest degree centrality and consensus scores in the String PPi network, and significant protein expression. GRB2 showed genomic alterations, highest degree centrality and consensus scores in the String PPi network, and substantial relevance in BC cell lines and PDXs. MED1 and GATA3 showed genomic alterations, significant protein expression, and considerable relevance in BC cell lines and PDXs. Lastly, BCL2, CTNNB1, EGFR and CDK2 showed significant protein expression, highest degree centrality and consensus scores in the String PPi network, and substantial relevance in BC cell lines and PDXs.
Relevant studies worldwide have identified OncoOmics BC essential genes. For instance, genome-wide association studies performed by the Breast Cancer Association Consortium showed that BRCA2, CHEK2, ESR1, FGFR2, MDM4 and PIK3R3 carry germline variants associated with BC development [74] [75] [76] [77] . According to Bailey et al., identifying molecular cancer drivers is critical for precision oncology 32 . Their final consensus list was conformed by 29 BC driver genes, of them, 22 were OncoOmics BC essential genes (AKT1, ARID1A, BRCA1, CASP8,  CDH1, CDKN1B, CTCF, ERBB2, FOXA1, GATA3, KMT2C, KRAS, MAP2K4, MAP3K1, NCOR1, NF1, PIK3CA,  PIK3R1, PTEN, RB1, SF3B1 and TP53) . According to Gonzalez-Perez et al., the IntOGen-mutation platform summarizes somatic mutations involved in tumorigenesis 91 . Their final consensus list was conformed by 99 mutational BC driver genes, of them, 34 were identified by the OncoOmics strategy (TP53, PIK3CA, KMT2C, GATA3,  CDH1, MAP3K1, ESR1, PTEN, AKT1, NCOR1, ARID1A, MAP2K4, FOXA1, NF1, ERBB2, RB1, SF3B1, ERBB3 , CTCF, PIK3R1, ATM, FGFR2, BRCA1, CASP8, CREBBP, BRCA2, CDKN2A, KRAS, CDKN1B, NOTCH2, MAX, MDM4, EGFR and JAK2). Finally, the PCAWG Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas reported an integrative analysis of 2,658 whole-cancer genomes across 38 tumor types 92 . Regarding breast cancer, PCAWG identified 27 mutational BC driver genes, of them, 15 were OncoOmics BC essential genes (TP53, PIK3CA, MAP3K1, KMT2C, NOTCH2, SF3B1, PTEN, ARID1A, MAP2K4, AKT1, CTCF, FOXA1, RB1, CDKN2A and ATM).
According to Reimand et al., g:Profiler lets us know the enrichment map of the 140 OncoOmics BC essential genes 66 . The most significant GO: biological process was the positive regulation of macromolecule metabolic process, the GO: molecular function was phosphatidylinositol 3-kinase activity, the Reactome pathway was generic transcriptor pathway, and the most significant Human Phenotype Ontology term was breast carcinoma 68 . Subsequently, the most relevant network interactions of the GO: biological process and the Reactome pathways were related to immune system, tyrosine kinase, cell cycle and DNA repair terms (Figs. 9 and S2) 54, 66 .
There is currently great enthusiasm about immunotherapeutic strategies to treat BC 93 . The first approval of an immune checkpoint blockade agent for treatment of BC came in March 2019 when the anti-PD-L1 antibody atezolizumab was approved to be used with nab-paclitaxel in triple-negative BC patients 94,95 . 16 OncoOmics BC essential genes were associated with immunotherapy 61, 96 as shown in Fig. 8C . Kinases have been recognized as therapeutic targets due to their druggability and play a critical role in cell migration, differentiation, growth and survival 97 . 15 OncoOmics BC essential genes were kinomes 62 . Cell cycle comprises a series of events that drive cell division and DNA replication 98 . 12 OncoOmics BC essential genes were involved in cell cycle 63 . DNA repair signaling pathways work in concert to correct DNA lesions and maintain genome stability. Nevertheless, a defective DNA repair machinery causes BC development and progression 99 . 17 OncoOmics BC essential genes were involved in DNA repair 64 . RBPs are key players in post-transcriptional events and are emerging as critical modulators in BC [100] [101] [102] . Bioinformatics profiling of tumors have revealed the landscape of alterations in RBPs across cancer types [103] [104] [105] [106] . Lastly, 10 OncoOmics BC essential genes were RBPs 65 .
Regarding clinical trials reported on the OncoOmics BC essential proteins, the Open Targets Platform is an available resource for the integration of genomics and chemical data to aid systematic drug target identification and prioritization 69 . There are 98 drugs that are being analyzed in 2,904 clinical trials in 28 of 140 OncoOmics BC essential proteins. Additionally, there are 30 drugs involved in 736 clinical trials in phases 3 and 4. The top five drugs with the highest number of clinical trials in process or completed are paclitaxel (111) , docetaxel (105), trastuzumab (80), tamoxifen (69) , and doxorubicin (60) 69 (Fig. 10e ).
Tumor-related genomic alterations predict tumor prognosis, drug response, and toxicity 107 . Precision medicine provides patients with the most appropriate diagnostics and targeted therapies based on the 'omics' profile and other predictive and prognostic tests 108 . Therefore, precision medicine aims to deliver the right medicine to the right patient at the right dose at the right time, minimizing adverse effects and maximizing drug efficacy 109, 110 . Figure 11 shows comprehensive interactions between directed biological drugs and 50 OncoOmics BC essential proteins aimed to improve precision medicine in breast cancer.
In conclusion, since BC is a complex and heterogeneous disease, the study of different OncoOmics approaches is an effective way to reveal essential genes to better understand the molecular landscape of processes behind oncogenesis, and to develop better therapeutic treatments focused on pharmacogenomics and precision medicine.
Methods
OncoPrint of genomic alterations according to the Pan-Cancer Atlas. PCA has reported the clinical data of 1084 individuals with BC and it can be visualized in the Genomic Data Commons of the National Cancer Institute (https://gdc.cancer.gov/) and in the cBioPortal (http://www.cbioportal.org/) 47, 48 . The clinical annotations were age, pTNM classification, tumor type, tumor stage and race/ethnicity.
Additionally, PCA has reported genomic alterations (mRNA up-regulation, mRNA down-regulation, CNV amplification, CVN deep deletion, putative driver mutations and fusion gene) of 994 individuals. Putative mutations were analyzed through exome sequencing, CNVs through the Genomic Identification of Significant Targets in Cancer (GISTIC 2.0) 111, 112 , and mRNA expression through RNA Seq V2. We analyzed five gene sets in order to compare the frequency mean of genomic alterations among them. The first gene set (n = 177) was integrated by the non-cancer genes 113 . We calculated the OncoScore of non-cancer genes, taking out all genes from our study. The second gene set (n = 119) was the BC driver genes, according to The Network of Cancer Genes 60 . The third gene set (n = 84) was taken from our previous study where we developed a Consensus Strategy of prioritized Protein-protein interactome network. The PPi network with a highest confidence cutoff of 0.9 and zero node addition was created using the String Database, which takes into account predicted and known interactions 53 . The confidence scoring is the approximate probability that a predicted link exists between two enzymes in the same metabolic map, whereas the degree centrality of a node means the number of edges the node has to other nodes in a network. The centrality indexes calculation and network visualization were analyzed through the Cytoscape software 54 . Proteins with the highest degree centrality, consensus score and sub-networks were differentiated by colors in the PPi network. On the other hand, OncoPPi (http://oncoppi.emory.edu/) reports the development of a cancer-focused PPi network, identifying more than 260 high-confidence cancer-associated PPi 55, 56 . In addition, the OncoPPi BC network consisted of 16 proteins and 18 PPi experimentally analyzed in BC cell lines 55, 56 . The correlation of the degree centrality by means of Spearman P-value test between our String PPi network and the OncoPPi BC network allowed for the validation of all the high-confidence BC-focused PPi analyzed in cell lines 29 . Lastly, proteins with the highest degree centrality and consensus scoring made up the second OncoOmics approach.
Protein expression analysis. TCGA has reported the protein expression data of 994 individuals with BC through RPPA and mass spectrometry by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and it can be visualized in the cBioPortal 47, 48 . We analyzed the protein expression of 230 protein where Z-scores ≥ 2 mean a significant high protein expression and Z-scores ≤ −2 mean a significant low protein expression.
On the other hand, the Human Protein Atlas (https://www.proteinatlas.org/) explains the diverse molecular signatures of proteomes in human tissues based on an integrated 'omics' approach that involves quantitative transcriptomics and tissue microarray-based immunohistochemistry 58, 88, 115 . We compared the protein expression levels (high, medium, low and non-detected) of our 230 proteins between normal and BC tissues. Finally, all genes with the altered protein expression made up the third OncoOmics approach.
Breast cancer dependency map. The DepMap project (https://depmap.org/portal/) is collaboration between the Broad Institute and the Welcome Sanger Institute. Multiple genetic or epigenetic changes provide cancer cells with specific vulnerabilities that normal cells lack. Even though the landscape of genomic alterations has been extensively studied to date, we have limited understanding of the biological impact of these alterations in the development of specific tumor vulnerabilities, which triggers a limited use of precision medicine in the clinical practice worldwide. Therefore, the main goal of DepMap is to create a comprehensive preclinical reference map connecting tumor features with tumor dependencies to accelerate the development of precision treatments [19] [20] [21] [22] .
In order to identify essential genes for BC cell proliferation and survival, DepMap performed systematic loss-of-function screens in a large number of well-annotated BC cell lines representing the tumor heterogeneity and their molecular subtypes. The DEMETER2 algorithm was applied to analyze genome-scale RNAi loss-of-function screens in 73 BC cell lines and 711 cancer cell lines, whereas the CERES algorithm was applied to analyze genome-scale CRISPR-Cas9 loss-of-function screens in 28 BC cell lines and 558 cancer cell lines 20, 22 . In addition to existing cell lines, the Cancer Cell Line Encyclopedia (CCLE) project will greatly expand the collection of characterized cell lines to improve precision treatments 116 .
Regarding dependency scores, a lower score means that a gene is more likely to be dependent in a specific cancer cell line. A score of 0 means that a gene is not essential, whereas a score of −1 corresponds to the median of all common essential genes. A strongly selective gene means that its dependency is at least 100 times more likely to have been sampled from a skewed distribution than a normal distribution. A common essential gene is when in a pan-cancer screen its gene ranks in the top most depleting genes in at least 90% of cell lines 19 . All genes or proteins with a dependency score ≤ −1 were subsequently analyzed with patient-derived xenografts.
Patient-derived xenografts. The Jackson Laboratory PDX resource (http://tumor.informatics.jax.org/ mtbwi/pdxSearch.do) comprises 455 PDX models originating from 34 different primary sites 59 . Even though, we analyzed expression levels of strongly selective and common essential proteins in breast cancer obtained from the analysis of BC dependency map in cell lines. Significant high protein expression has a Z-score ≥ 2 and significant low protein expression has a Z-scores ≤ −2.
Precision medicine. Precision oncology focuses on matching the most effective treatment based on the 'omics' profile of each individual or population 70, 71 . The CGI (https://www.cancergenomeinterpreter.org/home) flags genomic biomarkers of drug response with different levels of clinical relevance 38 . Huang et al. and the Pan-Cancer Atlas project conducted the largest investigation of pathogenic germline variants in cancer 73 . Long et al. 74, 75 , Cai et al. 76 , and Michailidou et al. 77 , performed genome-wide association studies identifying germline variations related to BC development. PreMedKB (http://www.fudan-pgx.org/premedkb/index.html#/home) is a bioinformatics tool that facilitates the interpretation of the clinical meaning of a patient's genetic variants 71 . PharmGKB (https://www.pharmgkb.org/) collected complete guidelines for application of pharmacogenomics in clinical practice, according to several consortiums worldwide [43] [44] [45] [46] . Finally, PCAWG Consortium (https://dcc.icgc. org/) revealed an integrative analysis of genomic alterations in coding and non-coding regions 6, 92 .
Based on the aforementioned somatic and germline oncogenic variants we performed two analyses. On the one hand, we analyzed the consequence type of variants with the Ensembl Variant Effector Predictor (https:// www.ensembl.org/Multi/Tools/VEP?db=core), which is a powerful toolset for the annotation of genomic variants in coding and non-coding regions 80 . On the other hand, we analyzed oncogenic variants through the Cancer Genome Interpreter and PreMedKB platforms to provide a comprehensive in silico list of biological therapy drugs 38, 71 .
Statistical analyses.
We performed a multiple comparison using the Bonferroni correction test (significant level of P < 0.05 and a 95% confidence interval) to analyze: 1) significant differences of genomic alteration frequencies among non-cancer genes, BC driver genes, Consensus Strategy, Pan-Cancer Atlas and PharmGKB/CGI genes; 2) significant differences of genomic alteration frequencies among intrinsic molecular subtypes and tumor stages; 3) significant differences of genomic alteration frequencies of signaling pathways among molecular subtypes and tumor stages. A significant correlation of the degree centrality between the String PPi network and the OncoPPi BC network was performed using the Spearman p-value test with a P < 0.05. The significant high and low protein expression in humn tissues and patient-derived xenografts was considered using the Z-score. Z-score ≥ 2 means significant high protein expression and Z-scores ≤ −2 means significant low protein expression. Lastly, the enrichment map of OncoOmics BC essential genes was performed using g:Profiler that determines the most significant GO: biological processes, GO: molecular functions, Reactome pathways, WikiPathways, KEGG pathways and human phenotype ontology with a false discovery rate <0.001.
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